Cargando…

Analysis of Hepatitis C Virus Decline during Treatment with the Protease Inhibitor Danoprevir Using a Multiscale Model

The current paradigm for studying hepatitis C virus (HCV) dynamics in patients utilizes a standard viral dynamic model that keeps track of uninfected (target) cells, infected cells, and virus. The model does not account for the dynamics of intracellular viral replication, which is the major target o...

Descripción completa

Detalles Bibliográficos
Autores principales:	Rong, Libin, Guedj, Jeremie, Dahari, Harel, Coffield, Daniel J., Levi, Micha, Smith, Patrick, Perelson, Alan S.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2013
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3597560/ https://www.ncbi.nlm.nih.gov/pubmed/23516348 http://dx.doi.org/10.1371/journal.pcbi.1002959

Ejemplares similares

First clinical study using HCV protease inhibitor danoprevir to treat COVID-19 patients
por: Chen, Hongyi, et al.
Publicado: (2020)

Danoprevir for the Treatment of Hepatitis C Virus Infection: Design, Development, and Place in Therapy
por: Miao, Miao, et al.
Publicado: (2020)

A New Age-Structured Multiscale Model of the Hepatitis C Virus Life-Cycle During Infection and Therapy With Direct-Acting Antiviral Agents
por: Quintela, Barbara de M., et al.
Publicado: (2018)

Efficacy and Safety of 12-week Interferon-based Danoprevir Regimen in Patients with Genotype 1 Chronic Hepatitis C
por: Wei, Lai, et al.
Publicado: (2019)

The paradox of highly effective sofosbuvir-based combination therapy despite slow viral decline: can we still rely on viral kinetics?
por: Nguyen, Thi Huyen Tram, et al.
Publicado: (2017)

Efficacy and safety of danoprevir plus sofosbuvir in GT 1, 2, 3, or 6 chronic hepatitis C patients with or without cirrhosis in China
por: Pan, Shufang, et al.
Publicado: (2021)

Clinical trial simulation to evaluate power to compare the antiviral effectiveness of two hepatitis C protease inhibitors using nonlinear mixed effect models: a viral kinetic approach
por: Laouénan, Cédric, et al.
Publicado: (2013)

Prevalence of end of treatment RNA-positive/sustained viral response in HCV patients treated with sofosbuvir combination therapies
por: Malespin, Miguel, et al.
Publicado: (2016)

Modeling Latently Infected Cell Activation: Viral and Latent Reservoir Persistence, and Viral Blips in HIV-infected Patients on Potent Therapy
por: Rong, Libin, et al.
Publicado: (2009)

Zika virus dynamics: Effects of inoculum dose, the innate immune response and viral interference
por: Best, Katharine, et al.
Publicado: (2021)

Multiscale profiling of protease activity in cancer
por: Amini, Ava P., et al.
Publicado: (2022)

Hepatitis delta virus RNA decline post-inoculation in human NTCP transgenic mice is biphasic
por: Maya, Stephanie, et al.
Publicado: (2023)

Understanding the antiviral effects of RNAi-based therapy in HBeAg-positive chronic hepatitis B infection
por: Kadelka, Sarah, et al.
Publicado: (2021)

Success of prophylactic antiviral therapy for SARS-CoV-2: Predicted critical efficacies and impact of different drug-specific mechanisms of action
por: Czuppon, Peter, et al.
Publicado: (2021)

A Multiscale Model of COVID-19 Dynamics
por: Wang, Xueying, et al.
Publicado: (2022)

Modeling hepatitis C virus kinetics during liver transplantation reveals the role of the liver in virus clearance
por: Shekhtman, Louis, et al.
Publicado: (2021)

Efficient Methods for Parameter Estimation of Ordinary and Partial Differential Equation Models of Viral Hepatitis Kinetics
por: Churkin, Alexander, et al.
Publicado: (2020)

Dominance of the CD4(+) T helper cell response during acute resolving hepatitis A virus infection
por: Zhou, Yan, et al.
Publicado: (2012)

Modeling-Based Response-Guided Hepatitis C Treatment During Pregnancy and Postpartum
por: Kushner, Tatyana, et al.
Publicado: (2023)

Rapid monophasic HBsAg decline during nucleic-acid polymer–based therapy predicts functional cure
por: Hershkovich, Leeor, et al.
Publicado: (2023)

Quantifying the Diversification of Hepatitis C Virus (HCV) during Primary Infection: Estimates of the In Vivo Mutation Rate
por: Ribeiro, Ruy M., et al.
Publicado: (2012)

Hepatitis B and Hepatitis D Viruses: A Comprehensive Update with an Immunological Focus
por: Sausen, Daniel G., et al.
Publicado: (2022)

Agent-Based Model Forecasts Aging of the Population of People Who Inject Drugs in Metropolitan Chicago and Changing Prevalence of Hepatitis C Infections
por: Gutfraind, Alexander, et al.
Publicado: (2015)

Timing of Antiviral Treatment Initiation is Critical to Reduce SARS‐CoV‐2 Viral Load
por: Gonçalves, Antonio, et al.
Publicado: (2020)

Protease inhibitors for the treatment of hepatitis C virus infection
por: de Leuw, Philipp, et al.
Publicado: (2017)

The Therapeutic Approaches for Hepatitis C Virus: Protease Inhibitors and Polymerase Inhibitors
por: Kwo, Paul Y., et al.
Publicado: (2011)

Modeling Within-Host Dynamics of Influenza Virus Infection Including Immune Responses
por: Pawelek, Kasia A., et al.
Publicado: (2012)

Modeling-Based Response-Guided DAA Therapy for Chronic Hepatitis C to Identify Individuals for Shortening Treatment Duration
por: Goyal, Ashish, et al.
Publicado: (2022)

People who inject drugs in metropolitan Chicago: A meta-analysis of data from 1997-2017 to inform interventions and computational modeling toward hepatitis C microelimination
por: Boodram, Basmattee, et al.
Publicado: (2022)

Inhibition Mechanism of SARS‐CoV‐2 Main Protease with Ketone‐Based Inhibitors Unveiled by Multiscale Simulations: Insights for Improved Designs
por: Ramos‐Guzmán, Carlos A., et al.
Publicado: (2021)

Asunaprevir, a protease inhibitor for the treatment of hepatitis C infection
por: Gentile, Ivan, et al.
Publicado: (2014)

A Hepatitis C Virus Infection Model with Time-Varying Drug Effectiveness: Solution and Analysis
por: Conway, Jessica M., et al.
Publicado: (2014)

Mathematical Modeling of Hepatitis C Prevalence Reduction with Antiviral Treatment Scale-Up in Persons Who Inject Drugs in Metropolitan Chicago
por: Echevarria, Desarae, et al.
Publicado: (2015)

Mathematical modeling of hepatitis C RNA replication, exosome secretion and virus release
por: Zitzmann, Carolin, et al.
Publicado: (2020)

Variability and resistance mutations in the hepatitis C virus NS3 protease in patients not treated with protease inhibitors
por: Zeminian, Luciana Bonome, et al.
Publicado: (2013)

Antibody Responses during Hepatitis B Viral Infection
por: Ciupe, Stanca M., et al.
Publicado: (2014)

Efficacy and Safety of All-oral, 12-week Ravidasvir Plus Ritonavir-boosted Danoprevir and Ribavirin in Treatment-naïve Noncirrhotic HCV Genotype 1 Patients: Results from a Phase 2/3 Clinical Trial in China
por: Xu, Xiaoyuan, et al.
Publicado: (2019)

A Robust and Efficient Numerical Method for RNA-Mediated Viral Dynamics
por: Reinharz, Vladimir, et al.
Publicado: (2017)

Treatment-Mediated Alterations in HIV Fitness Preserve CD4(+) T Cell Counts but Have Minimal Effects on Viral Load
por: Vaidya, Naveen K., et al.
Publicado: (2010)

Between Protein Fold and Nucleophile Identity: Multiscale Modeling of the TEV Protease Enzyme–Substrate Complex
por: Zlobin, Alexander, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_l40l5lhbcfugv8dc1s9qt2ms4m